Clinical TrialsScholar Rock recently announced highly compelling top line results from its Phase 2 EMBRAZE trial, reinforcing the clinical potential of apitegromab when used in combination with tirzepatide in obese and overweight patients.
Drug Development StrategyScholar Rock's decision to prioritize neuromuscular rare disease development is viewed as a savvy decision, avoiding more significant competition in obesity with large Pharma.
Myostatin InhibitionLead drug apitegromab could be the first effective and safe myostatin inhibitor, potentially providing significant motor function improvement to SMA patients.